1 / 25

Tuberculosis Vaccine Development in Denmark

Tuberculosis Vaccine Development in Denmark. Joshua Woodworth Post Doctoral Fellow Marie Curie IIF Statens Serum Institut Copenhagen , Denmark. About Me…. - From Detroit, MI - B.S. in Biology, University of Michigan - PhD in Immunology, Harvard Medical School

robertjdavis
Télécharger la présentation

Tuberculosis Vaccine Development in Denmark

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Tuberculosis Vaccine Developmentin Denmark Joshua Woodworth Post Doctoral Fellow Marie Curie IIF StatensSerum Institut Copenhagen, Denmark

  2. About Me… • - From Detroit, MI • - B.S. in Biology, University of Michigan • - PhD in Immunology, Harvard Medical School • “T cell immune response to Tuberculosis Infection” • - Post Doc, TB Vaccine Development • Statens Serum Institut • Copenhagen, Denmark

  3. StatenSerum Institut (SSI)Copenhagen, Denmark • •       • Governmental Institute • Epidemiology • Medical sample Testing • Academics and Industry • Vaccine Development • HIV,TB, Malaria, Chlamydia, Strep A • Polio vaccine, BCG (TB vaccine) • Diagnostics • TB skin test (tuberculin)

  4. Tuberculosis is global health problem • 1/3 World Population latently infected • 8 million new TB cases annually • 1.5 million TB deaths annually • TB is the major cause of death of people with HIV/AIDS

  5. Tuberculosis Disease and Immunity T Cells CD4/CD8 Chemokines Reactivation Tuberculosis (5%) latency Inhalation of aerosolized M. tuberculosis Control of Infection (95%) Infection of Lung Alveolar Macrophages Primary Tuberculosis (~5% within 5 years)

  6. Vaccination against TB LATENT PHASE REACTIVATION ACUTE PHASE PHASE load 5 - 10% Bacterial 90 - 95% Disease Threshold Infection TIME Prophylactic Vaccination

  7. History of TB and Vaccines Development of current TB vaccine (BCG) 1921 Discovery of M.tuberculosis 1882

  8. Efficacy >80% Efficacy <20% <10 10-24 25-49 50-99 Rate per 100 thousand 100-249 250+ BCG is not effective against adult pulmonary TB

  9. TB vaccines currently in clinical trials EU SSI SSI SSI SSI Ottenhoff THM, Kaufmann SHE. (2012)PLoS Pathogens

  10. What’smissingfrom BCG? • Identification of key missing proteins • ESAT-6 (SSI) • TB Patients have immune responses to ESAT-6 • ESAT-6 is a virulence factor • Adding ESAT-6 back to BCG makes it more dangerous • (Pasteur Institute, Paris) Mtb BCG Harboe et al, IAI, 1996

  11. Vaccination with ESAT-6 protects from TB ESAT-6 D15ESAT-6 Non-Vaccinated X + ESAT-6 Adjuvant (CAF01) Lung Bacteria

  12. T cells target only one ‘epitope’ of ESAT-6 ESAT-6 D15ESAT-6 Non-Vaccinated X + T cell response ESAT-6 Adjuvant (CAF01) Lung Bacteria

  13. T cell responses against cryptic epitopes of ESAT-6 give protection ESAT-6 D15ESAT-6 Non-Vaccinated X T cell response Lung Bacteria

  14. T cell responses against cryptic epitopes of ESAT-6 give protection ESAT-6 D15ESAT-6 Non-Vaccinated X T cell response Lung Bacteria

  15. T cell responses against cryptic epitopes have improved functional profile ESAT-6 D15ESAT-6 Non-Vaccinated X T cell response T cell ‘exhaustion’

  16. T cell responses against cryptic epitopes have improved functional profile ESAT-6 D15ESAT-6 Non-Vaccinated X T cell response Look less like TB-driven T cells (which are associated with disease)

  17. load 5 - 10% Bacterial 90 - 95% Disease Threshold Infection TIME Post-infection Prophylactic Vaccination Vaccination

  18. WhyEurope? • Science is science everywhere • Strong research and technology an innovation environment • Collaborative research projects • Shared knowledge and tools • Build professional network

  19. Consortiums and Collaborative ResearchProjects • Local Collaborations • Copenhagen University • Danish Technical University • Herlev Hospital • Hvidovre Hospital • EU Projects • NEW TB VACC • - Max Plank, PasteurInst, GSK, Leiden Univ MC, more… • GENIVAC • CENTER FOR NANOVACCINES • SAFEVAC • International Collaborations • US, South Africa, India

  20. WhyEurope? Meetings

  21. WhyEurope? Meetings Personal Travel I grew up in Europe, where history comes from. - Eddie Izzard

  22. Work and life in Denmark… `

  23. Themes to include • •       Europe has a vibrant and attractive science, technology and innovation culture; • •       Europe provides opportunities for career development and advancement; • •       Europe's industry and research organizations offer challenging opportunities to work in world-class environments.

  24. + + ACUTE PHASE PROTEIN REACTIVATION PHASE PROTEIN LATENT PHASE PROTEIN load 5 - 10% Bacterial 90 - 95% Disease Threshold Infection TIME Post-infection Prophylactic Vaccination Vaccination

More Related